Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PRELIMINARY OUTCOMES FOLLOWING CRYOSURGICAL ABLATION OF THE PROSTATE IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CARCINOMA
Autore:
LONG JP; FALLICK ML; LAROCK DR; RAND W;
Indirizzi:
TUFTS NEW ENGLAND MED CTR,DEPT UROL BOSTON MA 02111 TUFTS NEW ENGLAND MED CTR,DEPT COMMUNITY HLTH BOSTON MA 00000
Titolo Testata:
The Journal of urology
fascicolo: 2, volume: 159, anno: 1998,
pagine: 477 - 484
SICI:
0022-5347(1998)159:2<477:POFCAO>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEFINITIVE RADIATION-THERAPY; EXTERNAL-BEAM RADIATION; QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; STAGES T1; CANCER; ANTIGEN; ADENOCARCINOMA; RADIOTHERAPY; BIOPSY;
Keywords:
PROSTATIC NEOPLASMS; CRYOSURGERY; PROSTATE-SPECIFIC ANTIGEN; MORBIDITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
58
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Long et al., "PRELIMINARY OUTCOMES FOLLOWING CRYOSURGICAL ABLATION OF THE PROSTATE IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CARCINOMA", The Journal of urology, 159(2), 1998, pp. 477-484

Abstract

Purpose: Cryosurgical ablation of the prostate is a novel therapeuticmodality that induces cell lysis in the prostate by direct application of low temperatures. We have been conducting an ongoing prospective pilot study of the use of cryosurgical prostate ablation in treating patients with nonmetastatic prostate adenocarcinoma since January 1993. Results in 145 consecutive patients with mean 36 months and minimum 12 months of followup are presented. Materials and Methods: Accrual wasopen to patients with clinical stages T1a to T3c prostate adenocarcinoma. Pelvic lymph node dissections were recommended but not required for patients with prostate specific antigen (PSA) greater than 15 ng./ml. before study entry. PSA changes, random prostate biopsy findings and morbidities after cryosurgical prostate ablation were recorded for each patient. Results: Overall actuarial rates at 42 months for maintaining PSA less than 0.3 and less than 1.0 were 59% and 66%, respectively. The overall actuarial progression-free rate at 60 months was 56%. Among 160 biopsies performed 16% showed some evidence of residual carcinoma. Overall crude rates of maintaining either a negative biopsy or PSA less than 0.3 at 6 and 24 months after cryosurgical prostate ablation were 87% and 73%, respectively. Significantly higher morbidities were seen in previously radiated patients undergoing cryosurgical prostate ablation compared to those with no prior radiation. Among nonradiated patients 85% experienced no significant morbidity after cryosurgical prostate ablation. Conclusions: Although preliminary, short-term outcomes after cryosurgical prostate ablation appear to be comparable to identical outcomes reported for external beam radiotherapy. Based on these results cryosurgical prostate ablation appears to be an effectivetherapeutic alternative for treating patients with localized prostateadenocarcinoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 12:46:35